The Campbell Report

GRANT CAMPBELL I have over 20 years experience in the financial services industry, 15 of which were as a financial advisor with two of Canada’s largest full service investment dealer. My articles have been published by Investor's Digest of Canada, The Northern Miner, Report on Mining Magazine and Resource World magazine.

Name:
Location: Nanaimo, British Columbia, Canada

I am a former Financial Advisor with a keen interest in the Global Financial Markets.

Thursday, December 07, 2006

Uranium on a Tear:

The price of uranium is up again due to increased concerns regarding supply. The commodity price has increased dramatically over the past two years up from $20.00 a pound in December 2004 to $64.00 a pound today and continues to power higher.

The recent announcement by Cameco (CCO-T) regarding the flooding at their Cigar Lake Mine and the uncertainty about when that project will be able to get back on line has created a fear of a long term supply shortage. Cameco is the global leader in the production of uranium and had planned to have Cigar Lake up and producing in the very near future, it is rumored that the flooding at the mine halt production for up to 5 years.

Other producers will benefit from the price increase as will any companies that can bring on new production in the relatively near future. There is a high potential that the uranium price could reach $100.00 a pound in the next year or so.

The shortage in current production is being made up from surplus military supplies, those supplies are finite and will likely run out in the next 4-5 years.

According to the World Nuclear Association there are 442 reactors operating, 28 under construction, 62 planned and 161 proposed. If all of theses new plants are completed the number of reactors will increase by 56% from current levels.

There is a huge opportunity for investors in the uranium sector, the commodity does not trade in an open market and investors will have to look at individual companies.

Cameco in the largest producer in the World and even with the set back at Cigar Lake offers excellent exposure to the sector. Cameco supplies approximately 20% of the global demand and holds the largest reserves with 550 million pound of combined proven and probable reserves. Cameco has just increased he annual dividend by 25% per share to 20 cents from16 cents.

Denison Mines (DEN-T) is an emerging second tier producer that has been on the acquisition trail over the past few months in an effort to vault up in the production ranks. DEN recently completed a merger with International Uranium Corp and is in the process of the take over of Omegacorp Limited an Australian uranium miner.

SXR Uranium One (SXR-T) is currently developing to properties the Dominion mine in South Africa and Honeymoon mine in Australia. The company expects top have the South African mine in production in early 2007 with an initial capacity of 2 million pounds of uranium annually moving to 4 million pounds by 2011. The Australian mine in forecast to be in production by 2008 with a production capacity of 800,000 pounds annually.

The uranium market appears to have the potential for a sustained move higher as demand continues to increase while supply is slowly coming on stream.

For more information go to www.campbellreport.com

Tuesday, December 05, 2006

Wi-LAN (WIN-T) breaks out:

Wi-LAN Inc yesterday announced a patent licensing deal with Nokia, that see Nokia paying $15.2 million and transferring 93 patents to Wi-LAN in exchange for the licensing of all of Wi-LAN’s wireless technology patents.

The patents that Wi-LAN has acquired will allow the company access to a new sector, the in the high speed internet space. Wi-LAN now has access to Asymmetric Digital Subscriber Line (ADSL) technology which the company believes will have to be licensed by a number of North American companies. The enhanced portfolio of patents positions Wi-LAN for growth over the next few years.

This is the largest patent licensing deal that Wi-LAN has completed and is the first since the company reorganized. Getting out of the hardware production business and concentrating on the licensing of the patents they have developed over the past few years.

The new CEO, James Skippen, has a background in this field and was previously the Vice President of patent licensing at Mosaid Technology Inc. The company exited the broadband wireless equipment business earlier this year selling the manufacturing facility and moving the head office from Calgary to Ottawa.

The company’s shares have been on a tear over the past two days and have now broken out past the previous high set in 2004. The increased momentum and volume are very encouraging indicators that Wi-LAN has started a new up trend phase. The break out has begun and the next target is $7.50 and this could happen relatively quickly.

see www.campbellreport.com for more

Monday, December 04, 2006

Pfizer Surprise hits Drug sector:

Pfizer (PFE-N) caught the market by surprise over the weekend with the announcement that the clinical trials of their promising new drug Torcetrpib have been stopped. The drug trials were being over seen by an independent monitoring agency which called for the suspension of the trial due to adverse patient reactions which have led to the dead of 82 of the participants in the trial.

The trial was being done on a global basis with 7,500 participants the cancellation of the trial sets Pfizer back regarding the potential for a replacement for their current cholesterol drug Lipitor. Torcetipib was expected to be used in combination with Lipitor as a new form of cholesterol fighting drugs.

Pfizer shares are down $3.24 to $24.62 or about 11.5% and have been a negative for the rest of the sector as well pulling down all of the other major drug company shares.

This is the main risk when investing in the drug and biotech sectors the market punishes disappointments and it can take a considerable amount of time before investors are willing to buy the shares again.

Investors who have the patients should be looking at Pfizer as a buy, the current sell off is a reaction to this one particular trial and seems to have dramatically discounted the other potential drugs in development.

For more information go to http://www.campbellreport.com/